Etanercept: anti-tumor necrosis factor therapy for rheumatoid arthritis

McGahan L
Record ID 31999009802
English, French
Authors' objectives:

To summarise the available evidence on the use of etanercept, a tumor necrosis factor (TNF) antagonist, in the treatment of rheumatoid arthritis.

Authors' recommendations: Canadian clinical and economic data comparing methotrexate and etanercept alone versus etanercept in combination with methotrexate would be necessary before informed predictions could be made on its cost-effectiveness in our health care system. While the direct costs of this therapy are high, if etanercept controls the disease more effectively than current treatments, or earlier in the progression of the disease, it may have incremental cost-effectiveness. In addition, factors such as the timing of initial treatment, adverse effects, and the possibility that anti-TNF therapies may reduce the patient's defense against infection and malignancy, must also be taken into consideration prior to implementation.
Authors' methods: Overview
Project Status: Completed
Year Published: 1999
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Arthritis, Rheumatoid
  • Costs and Cost Analysis
  • Tumor Necrosis Factor-alpha
  • Antibodies, Monoclonal
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
Contact Email:
Copyright: Canadian Coordinating Office for Health Technology Assessment
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.